Temporal interplay between efflux pumps and target mutations in development of antibiotic resistance in Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 4, 2012, Pages 1680-1685

  Singh, Renu ^a   Swick, Michelle C ^b   Ledesma, Kimberly R ^a   Yang, Zhen ^a   Hu, Ming ^a   Zechiedrich, Lynn ^b   Tama, Vincent H ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; DNA TOPOISOMERASE (ATP HYDROLYSING) A; LEVOFLOXACIN; MOXIFLOXACIN; PROTEIN PARC; QUINOLONE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; ESCHERICHIA COLI; GENE DELETION; GENE MUTATION; GENE OVEREXPRESSION; IN VITRO STUDY; INFECTION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PRESSURE; PRIORITY JOURNAL;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CULTURE MEDIA; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; GENE DELETION; MICROBIAL SENSITIVITY TESTS; MUTATION; OFLOXACIN; POLYMERASE CHAIN REACTION; QUINOLONES; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84863366486     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05693-11     Document Type: Article

References (42)

1. Boyd LB, et al. 2008. Increased fluoroquinolone resistance with time in Escherichia coli from >17,000 patients at a large county hospital as a function of culture site, age, sex, and location. BMC Infect. Dis. 8:4.
2. Breines DM, et al. 1997. Quinolone resistance locus nfxD of Escherichia coli is a mutant allele of the parE gene encoding a subunit of topoisomerase IV. Antimicrob. Agents Chemother. 41:175-179. (Pubitemid 26428151)
3. Cattaneo C, et al. 2008. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. J. Antimicrob. Chemother. 61:721-728. (Pubitemid 351321152)
4. Chang TM, et al. 2007. Characterization of fluoroquinolone resistance mechanisms and their correlation with the degree of resistance to clinically used fluoroquinolones among Escherichia coli isolates. J. Chemother. 19:488-494.
5. Chien SC, et al. 1997. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob. Agents Chemother. 41:2256-2260.
6. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing: 17th informational supplement. CLSI document M100-S17. CLSI, Wayne, PA.
7. Colombo AL, et al. 2009. Surveillance programs for detection and characterization of emergent pathogens and antimicrobial resistance: results from the Division of Infectious Diseases, UNIFESP. An. Acad. Bras. Cienc. 81:571-587.
8. D'Argenio DZ, Schumitzky A. 1997. ADAPT II user's guide: pharmacokinetic / pharmacodynamic systems analysis software. Biomedical simulations resource. University of Southern California, Los Angeles, CA.
9. Dunham SA, McPherson CJ, Miller AA. 2010. The relative contribution of efflux and target gene mutations to fluoroquinolone resistance in recent clinical isolates of Pseudomonas aeruginosa. Eur. J. Clin. Microbiol. Infect. Dis. 29:279-288.
10. Everett MJ, Jin YF, Ricci V, Piddock LJ. 1996. Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals. Antimicrob. Agents Chemother. 40:2380-2386. (Pubitemid 26328050)
11. Fabrega A, Madurga S, Giralt E, Vila J. 2009. Mechanism of action of and resistance to quinolones. Microb. Biotechnol. 2:40-61.
12. Fish DN, Chow AT. 1997. The clinical pharmacokinetics of levofloxacin. Clin. Pharmacokinet. 32:101-119. (Pubitemid 27104410)
13. Hawkey PM, Jones AM. 2009. The changing epidemiology of resistance. J. Antimicrob. Chemother. 64(Suppl. 1):i3-i10.
14. Heisig P, Tschorny R. 1994. Characterization of fluoroquinolone-resistant mutants of Escherichia coli selected in vitro. Antimicrob. Agents Chemother. 38:1284-1291. (Pubitemid 24170708)
15. Hooper DC. 2001. Emerging mechanisms of fluoroquinolone resistance. Emerg. Infect. Dis. 7:337-341. (Pubitemid 32374357)
16. Jumbe NL, et al. 2006. Quinolone efflux pumps play a central role in emergence of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50:310-317. (Pubitemid 43042937)
17. Kiser TH, Obritsch MD, Jung R, MacLaren R, Fish DN. 2010. Efflux pump contribution to multidrug resistance in clinical isolates of Pseudomonas aeruginosa. Pharmacotherapy 30:632-638.
18. Komp Lindgren P, Marcusson LL, Sandvang D, Frimodt-Moller N, Hughes D. 2005. Biological cost of single and multiple norfloxacin resistance mutations in Escherichia coli implicated in urinary tract infections. Antimicrob. Agents Chemother. 49:2343-2351. (Pubitemid 40734464)
19. Kronvall G. 2010. Antimicrobial resistance 1979-2009 at Karolinska Hospital, Sweden: normalized resistance interpretation during a 30-year follow-up on Staphylococcus aureus and Escherichia coli resistance development. APMIS 118:621-639.
20. Lee HH, Molla MN, Cantor CR, Collins JJ. 2010. Bacterial charity work leads to population-wide resistance. Nature 467:82-85.
21. Livak KJ, Schmittgen TD. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. (Pubitemid 34164012)
22. Lomovskaya O, et al. 1999. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 43:1340-1346. (Pubitemid 29259322)
23. Lomovskaya O, Watkins W. 2001. Inhibition of efflux pumps as a novel approach to combat drug resistance in bacteria. J. Mol. Microbiol. Biotechnol. 3:225-236. (Pubitemid 32257908)
24. Louie A, et al. 2007. In vitro infection model characterizing the effect of efflux pump inhibition on prevention of resistance to levofloxacin and ciprofloxacin in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51:3988-4000. (Pubitemid 350057798)
25. Ma D, Alberti M, Lynch C, Nikaido H, Hearst JE. 1996. The local repressor AcrR plays a modulating role in the regulation of acrAB genes of Escherichia coli by global stress signals. Mol. Microbiol. 19:101-112. (Pubitemid 26025873)
26. Marcusson LL, Frimodt-Moller N, Hughes D. 2009. Interplay in the selection of fluoroquinolone resistance and bacterial fitness. PLoS Pathog. 5:e1000541.
27. Mathai D, Jones RN, Pfaller MA, SENTRY Participant Group North America. 2001. Epidemiology and frequency of resistance among pathogens causing urinary tract infections in 1,510 hospitalized patients: a report from the SENTRY Antimicrobial Surveillance Program (North America). Diagn. Microbiol. Infect. Dis. 40:129-136. (Pubitemid 32735552)
28. Morgan-Linnell SK, Becnel Boyd L, Steffen D, Zechiedrich L. 2009. Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 53:235-241.
29. Morgan-Linnell SK, Zechiedrich L. 2007. Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 51:4205-4208. (Pubitemid 350057831)
30. Nakamura S, Nakamura M, Kojima T, Yoshida H. 1989. gyrA and gyrB mutations in quinolone-resistant strains of Escherichia coli. Antimicrob. Agents Chemother. 33:254-255. (Pubitemid 19053872)
31. Piddock LJ. 2006. Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. Clin. Microbiol. Rev. 19:382-402.
32. Piddock LJ. 1999. Mechanisms of fluoroquinolone resistance: an update 1994-1998. Drugs 58(Suppl. 2):11-18. (Pubitemid 29500079)
33. Pumbwe L, Chang A, Smith RL, Wexler HM. 2006. Clinical significance of overexpression of multiple RND-family efflux pumps in Bacteroides fragilis isolates. J. Antimicrob. Chemother. 58:543-548. (Pubitemid 44288117)
34. Ricci V, Tzakas P, Buckley A, Piddock LJ. 2006. Ciprofloxacin-resistant Salmonella enterica serovar Typhimurium strains are difficult to select in the absence of AcrB and TolC. Antimicrob. Agents Chemother. 50:38-42. (Pubitemid 43042899)
35. Saito R, et al. 2006. Role of type II topoisomerase mutations and AcrAB efflux pump in fluoroquinolone-resistant clinical isolates of Proteus mirabilis. J. Antimicrob. Chemother. 58:673-677. (Pubitemid 44288138)
36. Singh R, et al. 2009. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model. J. Antimicrob. Chemother. 64:556-562.
37. Swick MC, Morgan-Linnell SK, Carlson KM, Zechiedrich L. 2011. Expression of multidrug efflux pump genes acrAB-tolC, mdfA, and norE in Escherichia coli clinical isolates as a function of fluoroquinolone and multidrug resistance. Antimicrob. Agents Chemother. 55:921-924.
38. Tam VH, et al. 2005. Bacterial-population responses to drug-selective pressure: examination of garenoxacin's effect on Pseudomonas aeruginosa. J. Infect. Dis. 192:420-428. (Pubitemid 41023120)
39. Tam VH, et al. 2007. Impact of drug-exposure intensity and duration of therapy on the emergence of Staphylococcus aureus resistance to a quinolone antimicrobial. J. Infect. Dis. 195:1818-1827. (Pubitemid 46870255)
40. Vila J, et al. 1994. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother. 38:2477-2479. (Pubitemid 24304253)
41. Webber MA, Piddock LJ. 2003. The importance of efflux pumps in bacterial antibiotic resistance. J. Antimicrob. Chemother. 51:9-11. (Pubitemid 36163821)
42. Yang S, Clayton SR, Zechiedrich EL. 2003. Relative contributions of the AcrAB, MdfA and NorE efflux pumps to quinolone resistance in Escherichia coli. J. Antimicrob. Chemother. 51:545-556. (Pubitemid 36336146)